Indivior Pharmaceuticals (INDV) Capital Expenditures (2024 - 2026)

Indivior Pharmaceuticals' Capital Expenditures history runs 3 years deep, the most recent figure standing at $20.0 million for Q1 2026.

• On a quarterly basis, Capital Expenditures rose 300.0% year-over-year to $20.0 million in Q1 2026; TTM through Mar 2026 was $81.0 million, a 153.12% increase from a year earlier, with the FY2025 full-year figure at $66.0 million, up 127.59% from the prior year.
• Capital Expenditures declined to $20.0 million in Q1 2026 per INDV's latest filing, from $24.0 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $24.0 million in Q4 2025 and bottomed at $2.0 million in Q1 2024.
• The 3-year median for Capital Expenditures is $16.0 million (2024), against an average of $12.8 million.
• Biggest YoY gain for Capital Expenditures was 325.0% in 2025; the steepest drop was 50.0% in 2025.
• Year by year, Capital Expenditures stood at $16.0 million in 2024, then surged by 50.0% to $24.0 million in 2025, then retreated by 16.67% to $20.0 million in 2026.
• Per Business Quant, the three latest INDV Capital Expenditures figures stand at $20.0 million (Q1 2026), $24.0 million (Q4 2025), and $20.0 million (Q3 2025).